Consenting schizophrenic patients ranging in age from 18 to 63 years were 
withdrawn from antipsychotics for at least 1 week and randomly assigned to 
receive identical capsules of thioridazine (n = 13), molindone (n = 10), or 
haloperidol (n = 12) for a minimum of 6 weeks. Compared with the molindone- and 
haloperidol-treated patients, the thioridazine-treated patients were 
significantly improved over time as measured by Brief Psychiatric Rating Scale 
(BPRS) and Hamilton Rating Scale for Depression (HAM-D) total scores. 
Improvement in BPRS scores was due largely to improvement in symptoms of anxiety 
and depression. Subjects did not differ significantly on other measures, with 
the important exception of weight. On average, molindone patients lost 5 pounds 
over the 6 weeks of treatment, whereas thioridazine patients gained 6 pounds. 
Haloperidol-treated patients had no significant weight changes.